224 related articles for article (PubMed ID: 31636099)
21. ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma.
Cao M; Lai P; Liu X; Liu F; Qin Y; Tu P; Wang Y
Front Immunol; 2023; 14():1282996. PubMed ID: 38223508
[TBL] [Abstract][Full Text] [Related]
22. CSF1R regulates schizophrenia-related stress response and vascular association of microglia/macrophages.
Yan L; Li Y; Fan F; Gou M; Xuan F; Feng W; Chithanathan K; Li W; Huang J; Li H; Chen W; Tian B; Wang Z; Tan S; Zharkovsky A; Hong LE; Tan Y; Tian L
BMC Med; 2023 Aug; 21(1):286. PubMed ID: 37542262
[TBL] [Abstract][Full Text] [Related]
23. Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment.
Maldonado MDM; Schlom J; Hamilton DH
Cancer Immunol Immunother; 2023 Oct; 72(10):3349-3362. PubMed ID: 37505292
[TBL] [Abstract][Full Text] [Related]
24. Neuronal apoptosis drives remodeling states of microglia and shifts in survival pathway dependence.
Anderson SR; Roberts JM; Ghena N; Irvin EA; Schwakopf J; Cooperstein IB; Bosco A; Vetter ML
Elife; 2022 Apr; 11():. PubMed ID: 35481836
[TBL] [Abstract][Full Text] [Related]
25. Genetic and Immunohistochemistry Tools to Visualize Rat Macrophages In Situ.
Huang S; Carter-Cusack D; Maxwell E; Patkar OL; Irvine KM; Hume DA
Methods Mol Biol; 2024; 2713():99-115. PubMed ID: 37639117
[TBL] [Abstract][Full Text] [Related]
26. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor.
Tap WD; Healey JH
Tumour Biol; 2022; 44(1):239-248. PubMed ID: 36502356
[TBL] [Abstract][Full Text] [Related]
27. Role of CSF1R 550th-tryptophan in kusunokinin and CSF1R inhibitor binding and ligand-induced structural effect.
Chompunud Na Ayudhya C; Graidist P; Tipmanee V
Sci Rep; 2024 May; 14(1):12531. PubMed ID: 38822100
[TBL] [Abstract][Full Text] [Related]
28. Distinguishing the effects of systemic CSF1R inhibition by PLX3397 on microglia and peripheral immune cells.
Okojie AK; Uweru JO; Coburn MA; Li S; Cao-Dao VD; Eyo UB
J Neuroinflammation; 2023 Oct; 20(1):242. PubMed ID: 37865779
[TBL] [Abstract][Full Text] [Related]
29. Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18.
Miyauchi S; Arimoto KI; Liu M; Zhang Y; Zhang DE
Cell Rep; 2023 Dec; 42(12):113560. PubMed ID: 38100351
[TBL] [Abstract][Full Text] [Related]
30. Control of macrophage metabolism and activation by mTOR and Akt signaling.
Covarrubias AJ; Aksoylar HI; Horng T
Semin Immunol; 2015 Aug; 27(4):286-96. PubMed ID: 26360589
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR.
Ortega-Molina A; Deleyto-Seldas N; Carreras J; Sanz A; Lebrero-Fernández C; Menéndez C; Vandenberg A; Fernández-Ruiz B; Marín-Arraiza L; de la Calle Arregui C; Belén Plata-Gómez A; Caleiras E; de Martino A; Martínez-Martín N; Troulé K; Piñeiro-Yáñez E; Nakamura N; Araf S; Victora GD; Okosun J; Fitzgibbon J; Efeyan A
Nat Metab; 2019 Aug; 1(8):775-789. PubMed ID: 31579886
[TBL] [Abstract][Full Text] [Related]
32. Amino acids suppress macropinocytosis and promote release of CSF1 receptor in macrophages.
Mendel ZI; Reynolds MB; Abuaita BH; O'Riordan MX; Swanson JA
J Cell Sci; 2022 Feb; 135(4):. PubMed ID: 35107133
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.
Lossos C; Liu Y; Kolb KE; Christie AL; Van Scoyk A; Prakadan SM; Shigemori K; Stevenson KE; Morrow S; Plana OD; Fraser C; Jones KL; Liu H; Pallasch CP; Modiste R; Nguyen QD; Craig JW; Morgan EA; Vega F; Aster JC; Sarosiek KA; Shalek AK; Hemann MT; Weinstock DM
Cancer Discov; 2019 Jul; 9(7):944-961. PubMed ID: 31040105
[TBL] [Abstract][Full Text] [Related]
34. Targeting the CSF-1/CSF-1R Axis: Exploring the Potential of CSF1R Inhibitors in Neurodegenerative Diseases.
Baek J; Jun J; Kim H; Bae H; Park H; Cho H; Han S; Shin HC; Hah JM
J Med Chem; 2024 Apr; 67(7):5699-5720. PubMed ID: 38530425
[TBL] [Abstract][Full Text] [Related]
35. Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from Flatland.
Bjørnstad F; Havik S; Aarhus TI; Mahdi I; Unger A; Habenberger P; Degenhart C; Eickhoff J; Klebl BM; Sundby E; Hoff BH
Eur J Med Chem; 2024 Feb; 265():116053. PubMed ID: 38141285
[TBL] [Abstract][Full Text] [Related]
36. Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia.
Sletta KY; Castells O; Gjertsen BT
Front Oncol; 2021; 11():654817. PubMed ID: 33842370
[TBL] [Abstract][Full Text] [Related]
37. CSF1R inhibition is not specific to innate immune cells but also affects T-helper cell differentiation independently of microglia depletion.
Lei F; Cui N; Zhou C; Chodosh J; Vavvas DG; Paschalis EI
Res Sq; 2023 Sep; ():. PubMed ID: 37720036
[TBL] [Abstract][Full Text] [Related]
38. CSF-1R: A promising therapeutic target for various diseases.
Wen CY; Chen PH; Hsieh FR; Chang R; Wu MY; Yong SB; Li CJ
Pharmacol Res; 2024 Jun; 204():107196. PubMed ID: 38677533
[No Abstract] [Full Text] [Related]
39. Assessment of Skin Biopsy as a Diagnostic Biomarker in CSF1R-Related Disorder.
Dulski J; Jiang P; Lin WL; Dickson DW; Wszolek ZK
Neurology; 2024 Jun; 102(11):e209437. PubMed ID: 38759141
[TBL] [Abstract][Full Text] [Related]
40. Embryonic inhibition of colony-stimulating factor 1 receptor impacts craniofacial morphogenesis.
Nagra A; Katsube M; Gao W; Rosin JM; Vora SR
Orthod Craniofac Res; 2023 Dec; 26 Suppl 1():20-28. PubMed ID: 37231583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
